First-Year Experiences with the Interagency Guidelines for Drug Donations
(2000; 51 pages)

Table of Contents

	Acknowledgements
	Executive summary
	1. Introduction
		Short history of the concept of "good donation practice"
		Objective of the study
		Outline of the report
	2. Sources of information and study methodology
		General overview of the method
		Definition of respondents
		Questionnaires
		Distribution of questionnaires
		Inclusion criteria
		Sample size
		Data analysis
	3. Dissemination and uptake of the Guidelines
		The development stage: September 1994 - May 1996
		The launch: May 1996
		After May 1996: dissemination of the Guidelines
		Other publications about drug donations
		Conferences at which the Guidelines were discussed
		International organizations subscribing to the Guidelines
		Countries and national organizations that have adapted or adopted the Guidelines
		Other country studies on drug donations
	4. Basic characteristics of drug donations
		Magnitude of donations made in the past 12 months
		Cost basis of donation value
		Percentage of donations made for emergencies
		Percentage of donations based on specific requests
	5. Practical benefits as a result of the Guidelines
		General benefits
		Specific benefits for recipients
	6. Drug donations which were hampered, delayed or cancelled
	7. Experiences and opinions regarding the 12-month shelf-life requirement
		Impact of the Guidelines
		Guidelines by other organizations
		Agreement with the current provision
		Problems with the Guidelines
		Arguments for and against the 12-month shelf-life provision
		Recommendations
	8. Other suggestions to improve the Guidelines
		Recommendation
	9. How could donation practice be further improved?
		Discussing the Guidelines improves donation practice
		Give more practical advice on good donation practice
		Recommendations
	10. Summary of recommendations
	11. Postscript
	References

First-Year Experiences with the Interagency Guidelines for Drug Donations

WHO/EDM/PAR/2000.1
English only
Distribution: limited

Department of Essential Drugs and Medicines Policy
World Health Organization

Authors

Ms Radha Asher
Dr Robin Gray
Dr Hans Hogerzeil

Department of Essential Drugs and Medicines Policy
World Health Organization, Geneva

Quotation from an individual health institution:

We see the Guidelines as a help to us, to continue to provide essential services to as many patients as possible, and at reasonable cost. We also see the Guidelines as a necessary component in the development of a health care system that is sustainable, encouraging recipients and patients to take more responsibility in the management of health care delivery.

© World Health Organization 2000
________________________________________
This document is not issued to the general public, and all rights are reserved by the World Health Organization (WHO).
The document may not be reviewed, abstracted, quoted, reproduced or translated, in part or in whole, without the prior written permission of WHO. No part of this document may be stored in a retrieval system or transmitted in any form or by any means - electronic, mechanical or other - without the prior permission of WHO.

The views expressed in documents by named authors are solely the responsibility of those authors.